Immunoprecipitation of LAI From HL-60 CM
| . | CFU-GM in S-Phase (%) . |
|---|---|
| Medium control | 34.1 |
| HL-60 CM untreated | 24.7* |
| HL-60 CM + anti-MPO | 21.7* |
| HL-60 CM + antielastase | 23.0* |
| HL-60 CM + anticathepsin G | 22.1* |
| HL-60 CM + anti-PR3 (MoAb) | 33.6 |
| HL-60 CM + anti-PR3 | 41.3 |
| . | CFU-GM in S-Phase (%) . |
|---|---|
| Medium control | 34.1 |
| HL-60 CM untreated | 24.7* |
| HL-60 CM + anti-MPO | 21.7* |
| HL-60 CM + antielastase | 23.0* |
| HL-60 CM + anticathepsin G | 22.1* |
| HL-60 CM + anti-PR3 (MoAb) | 33.6 |
| HL-60 CM + anti-PR3 | 41.3 |
The number of CFU-GM in the medium control was 225 ± 7/dish and 149 ± 6/dish in the cytosine arabinoside-treated control. Anti-MPO was used as a negative control antibody. All antibodies were rabbit polyclonal except one, ie, monoclonal anti-PR3.
Abbreviations: MPO, myeloperoxidase; MoAb, monoclonal antibody.
Denotes significant reduction of CFU-GM in S-phase (P < .05).